Zhejiang Orient Gene Biotech Co., Ltd (SHA:688298)
22.42
-0.50 (-2.18%)
Apr 24, 2025, 2:45 PM CST
SHA:688298 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2019 |
---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2019 |
Operating Revenue | 826.71 | 812.34 | 8,741 | 10,152 | 3,255 | Upgrade
|
Other Revenue | - | 7.81 | 27.23 | 16.98 | 10.61 | Upgrade
|
Revenue | 826.71 | 820.16 | 8,768 | 10,169 | 3,265 | Upgrade
|
Revenue Growth (YoY) | 0.80% | -90.65% | -13.78% | 211.43% | 788.83% | Upgrade
|
Cost of Revenue | - | 640.51 | 5,158 | 2,682 | 753.24 | Upgrade
|
Gross Profit | 826.71 | 179.64 | 3,610 | 7,487 | 2,512 | Upgrade
|
Selling, General & Admin | - | 534.55 | 755.81 | 1,133 | 356.81 | Upgrade
|
Research & Development | - | 260.86 | 511.56 | 428.52 | 93.75 | Upgrade
|
Other Operating Expenses | 1,393 | 14.22 | 89.16 | 72.75 | 20.52 | Upgrade
|
Operating Expenses | 1,393 | 839.8 | 1,350 | 1,667 | 500.45 | Upgrade
|
Operating Income | -565.84 | -660.15 | 2,260 | 5,820 | 2,012 | Upgrade
|
Interest Expense | - | -18.12 | -6.97 | -0.94 | -0.04 | Upgrade
|
Interest & Investment Income | - | 249.68 | 122.87 | 46.02 | 19.96 | Upgrade
|
Currency Exchange Gain (Loss) | - | 87.17 | 495.21 | -99.72 | -61.55 | Upgrade
|
Other Non Operating Income (Expenses) | -5.63 | 1.5 | -2.44 | -2.09 | -3.46 | Upgrade
|
EBT Excluding Unusual Items | -571.46 | -339.92 | 2,869 | 5,763 | 1,967 | Upgrade
|
Impairment of Goodwill | - | -57.31 | -15.41 | - | - | Upgrade
|
Gain (Loss) on Sale of Investments | - | -8.99 | 1.66 | 0.04 | - | Upgrade
|
Gain (Loss) on Sale of Assets | - | -0.64 | -0.13 | -0.04 | -0.03 | Upgrade
|
Asset Writedown | - | -6.09 | -351.04 | - | - | Upgrade
|
Other Unusual Items | - | 8.72 | -33.16 | 6.71 | 7.75 | Upgrade
|
Pretax Income | -571.46 | -404.23 | 2,471 | 5,770 | 1,974 | Upgrade
|
Income Tax Expense | -59.86 | 14.04 | 373.32 | 829.32 | 293.95 | Upgrade
|
Earnings From Continuing Operations | -511.6 | -418.27 | 2,097 | 4,941 | 1,680 | Upgrade
|
Minority Interest in Earnings | - | 20.69 | -29.72 | -20.46 | -2.97 | Upgrade
|
Net Income | -511.6 | -397.58 | 2,068 | 4,920 | 1,677 | Upgrade
|
Net Income to Common | -511.6 | -397.58 | 2,068 | 4,920 | 1,677 | Upgrade
|
Net Income Growth | - | - | -57.98% | 193.33% | 1942.94% | Upgrade
|
Shares Outstanding (Basic) | 197 | 202 | 202 | 202 | 197 | Upgrade
|
Shares Outstanding (Diluted) | 197 | 202 | 202 | 202 | 197 | Upgrade
|
Shares Change (YoY) | -2.50% | 0.13% | -0.02% | 2.16% | 30.20% | Upgrade
|
EPS (Basic) | -2.60 | -1.97 | 10.26 | 24.40 | 8.50 | Upgrade
|
EPS (Diluted) | -2.60 | -1.97 | 10.26 | 24.40 | 8.50 | Upgrade
|
EPS Growth | - | - | -57.97% | 187.12% | 1469.13% | Upgrade
|
Free Cash Flow | - | -2,642 | 1,944 | 4,696 | 1,663 | Upgrade
|
Free Cash Flow Per Share | - | -13.09 | 9.64 | 23.29 | 8.43 | Upgrade
|
Dividend Per Share | - | - | 1.667 | 3.679 | 2.500 | Upgrade
|
Dividend Growth | - | - | -54.69% | 47.14% | 1900.00% | Upgrade
|
Gross Margin | 100.00% | 21.90% | 41.18% | 73.63% | 76.93% | Upgrade
|
Operating Margin | -68.44% | -80.49% | 25.78% | 57.23% | 61.61% | Upgrade
|
Profit Margin | -61.88% | -48.48% | 23.58% | 48.38% | 51.37% | Upgrade
|
Free Cash Flow Margin | - | -322.09% | 22.17% | 46.18% | 50.94% | Upgrade
|
EBITDA | -416.16 | -510.48 | 2,338 | 5,849 | 2,019 | Upgrade
|
EBITDA Margin | -50.34% | -62.24% | 26.66% | 57.52% | 61.83% | Upgrade
|
D&A For EBITDA | 149.68 | 149.68 | 77.84 | 28.77 | 7.44 | Upgrade
|
EBIT | -565.84 | -660.15 | 2,260 | 5,820 | 2,012 | Upgrade
|
EBIT Margin | -68.44% | -80.49% | 25.78% | 57.23% | 61.61% | Upgrade
|
Effective Tax Rate | - | - | 15.11% | 14.37% | 14.89% | Upgrade
|
Revenue as Reported | - | 820.16 | 8,768 | 10,169 | 3,265 | Upgrade
|
Advertising Expenses | - | 24.52 | 13.47 | - | - | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.